Latest Breaking News On - Aquestive therapeutics inc - Page 14 : comparemela.com

Transmucosal Drug Delivery Pipeline Research Report 2023: Formulate Effective R&D Strategies with Key Insights

/PRNewswire/ The "Transmucosal Drug Delivery Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key.

United statesIsrael generalNew south walesLaura woodHarm reduction therapeutics incHebrew university of jerusalemProducts under developmentBespak europe ltdInternational partnershipUniversity of the witwatersrandLyra therapeutics incKytogenics pharmaceuticals incGrunenthal ltdFerring pharmaceuticalsRenown pharmaceuticals pvt ltdAtossa therapeutics inc

Aquestive Therapeutics Announces Positive Topline Pharmacokinetic Data for Anaphylm™ (epinephrine) Sublingual Film

Reports positive topline data from latest pilot pharmacokinetic studyPlans to submit pivotal PK clinical study protocol to the FDA in early AugustAnticipates commencement of its definitive pivotal PK.

United statesDaniel barberStephanie carringtonJohn oppenheimerExchange commissionClinical research at pulmonaryCompany or aquestiveAquestive therapeutics incAdministration of anaphylmAllergy associatesArea underExceeds lower bracketAll expected pivotalRelease chartAchieves targeted cmaxChief executive officer

Aquestive Therapeutics to Report Second Quarter 2023 Financial Results and Recent Business Highlights on August 7 and Host Conference Call on August 8 at 8:00 a m ET

Aquestive Therapeutics to Report Second Quarter 2023 Financial Results and Recent Business Highlights on August 7 and Host Conference Call on August 8 at 8:00 a m ET
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

Stephanie carringtonAquestive therapeutics incExchange commissionCompany or aquestiveAquestive therapeuticsSecond quarterPrivate securities litigation reform actAnnual reportQuarterly reportsCurrent reports

Aquestive Therapeutics to Present Positive Topline Data from Pharmacokinetic and

WARREN, N.J., July 25, 2023 (GLOBE NEWSWIRE) Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of

United statesDaniel barberJohn oppenheimerStephanie carringtonMedstar franklin squareRutgers university school of medicineCompany or aquestiveAquestive therapeutics incExchange commissionAspen allergy conferenceGlobal food allergy prevention summitChief executive officerEpinephrine sublingual film versus intra muscularDavid goldenFood exposureEpinephrine sublingual

Aquestive Therapeutics to Report Second Quarter 2023 Financial Results and Recent Business Highlights on August 7 and Host Conference Call on August 8 at 8: 00 a m ET

25.07.2023 - WARREN, N.J., July 25, 2023 (GLOBE NEWSWIRE) - Aquestive Therapeutics, Inc. (NASDAQ: AQST), (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide .

Stephanie carringtonExchange commissionAquestive therapeutics incSecond quarterPrivate securities litigation reform actAnnual reportQuarterly reportsCurrent reportsAquestive therapeuticsQuestive therapeutics to report second quarter 2023 financial results and recent business highlights on august 7 host conference call 8 at